Apogee Therapeutics Highlights Progress and Potential in Biologic Programs at R&D Day

On December 2, 2024, Apogee Therapeutics, a clinical-stage biotechnology company, released a press release detailing the significant advancements made in its novel biologic programs for Inflammatory and Immunology (I&I) diseases during its Virtual R&D Day. The event, held on the same day at 10:00 am Eastern Time, showcased the latest developments in the company’s pipeline.

The press release focused on updates related to key programs within Apogee Therapeutics:

APG808 Interim Phase 1 Trial Results:
– Positive results were shared from the APG808 Phase 1 trial, demonstrating a potential best-in-class pharmacokinetic (PK) profile with a half-life of approximately 55 days.
– APG808 exhibited sustained effectiveness on pharmacodynamic (PD) markers up to around 3 months, showing good tolerance across all dose levels.
– The company is currently evaluating APG808 in a Phase 1b trial for asthma, with anticipated data availability in the first half of 2025.

APG777 Program Advances:
– APG777, a novel monoclonal antibody targeting IL-13, displayed promising results with a 77-day half-life, supporting potential annual dosing which could revolutionize the treatment landscape for atopic dermatitis.
– Ongoing Phase 2 trials for AD are progressing well, with strong enrollment leading to the expectation of reporting 16-week topline data in mid-2025.
– Plans are in place for the development of APG777 in asthma and eosinophilic esophagitis, including the initiation of new trials in the coming year.

Innovative Combination Approaches:
– Apogee Therapeutics aims to enhance treatment options through innovative combination strategies addressing Types 1-3 inflammation to provide improved clinical responses and optimized dosing.
– The company plans to evaluate combinations such as APG777 + APG990 and APG777 + APG333 in various inflammatory conditions with potential for significant clinical benefits.

Overall, the Virtual R&D Day highlighted Apogee Therapeutics’ commitment to developing groundbreaking treatments for I&I diseases that offer superior efficacy, dosing convenience, and therapeutic outcomes. Investors and stakeholders witnessed the company’s dedication to advancing its pipeline towards addressing the unmet needs of patients living with these conditions. More updates and data are expected in the future as Apogee continues to innovate and make strides in the biopharmaceutical industry.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Apogee Therapeutics’s 8K filing here.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.